

Subject, City, State	Effective date	Subject, City, State	Effective date
Donigan, William T Jr, Osage City, KS .....	05/07/97	Moretti, Jeffrey S, Poughkeepsie, NY .....	05/06/97
Durojaye, Ojebode A, Bronx, NY .....	05/06/97	Murphy, Kevin V, Fraser, MI .....	04/28/97
Elia, Harry R, Woodcliff Lake, NJ .....	05/07/97	Navai, Mehdi N, Alhambra, CA .....	04/23/97
Fabrega, Cathye Davis, Monterey Park, CA .....	04/23/97	Neira, Alejandro III, Albuquerque, NM .....	04/27/97
Feldman, Donald S, Peekskill, NY .....	05/06/97	Norville, Michael T, Costa Mesa, CA .....	04/23/97
Formaker, James W, Santa Monica, CA .....	05/06/97	Nowroozi, Sohrab, New York, NY .....	05/06/97
Fulton, Debra, Toledo, OH .....	04/28/97	Patel, Narayan S, Jackson Heights, NY .....	05/07/97
Ganden, Richard S, Olean, NY .....	05/04/97	Rice, Sterling Thomas, Kansas City, MO .....	04/28/97
Ganiyu, Kehinde M, Dyer, IN .....	04/28/97	Rios, Emanuel J, Pasadena, CA .....	04/23/97
Gearhart, Cindy L, Lakewood, CA .....	05/06/97	Schleicher, Kyle S, Santa Monica, CA .....	04/23/97
Gonzalez, Nilda, Brooklyn, NY .....	05/07/97	Schwontkowski, Donna L, Salt Lake City, UT .....	05/07/97
Gray, Albert L, Lynbrook, NY .....	05/06/97	Spivey, Douglas V, Cape Coral, FL .....	05/05/97
Gregory, Edward S, Roosevelt, NY .....	05/06/97	Styler, Richard L, San Diego, CA .....	05/06/97
Harper, Tracy E, Natchitoches, LA .....	04/27/97	Tolbert, William Jr, Los Feliz, CA .....	04/23/97
Heese, Kit L, Carroll, IA .....	04/28/97	Tsiotsias, Artemios G, Hollywood, FL .....	05/05/97
Helgeson, Merle C, Newport, KY .....	05/05/97	Underwood, Paul D, Yonkers, NY .....	05/07/97
Hendricks, Craig B, Tyler, TX .....	04/27/97	Walters, Jerome P, Glendale, AZ .....	04/23/97
Hetzel, William A, Winchester, OH .....	04/28/97	Wilkes, Craig A, Corona, CA .....	04/23/97
Hobowsky, Martin R, Richmond Heights, OH .....	04/28/97	Worth, Kelly G, Anaheim, CA .....	05/06/97
Holloway, Jill B, Elmont, NY .....	05/04/97		
Hughes, Jill A, St James, NY .....	05/06/97		
Hughes, Joseph R Jr, San Diego, CA .....	04/23/97		
Iqal, Robert S, Claremont, CA .....	04/23/97		
Jenewari, Elsie, Sewell, NJ .....	05/06/97		
Johnson, Howard D, Bridgeville, PA .....	04/30/97		
Kent, Donald E, Berkeley, CA .....	04/23/97		
Knight, Patricia A, Sayville, NY .....	05/04/97		
Leconte, Isabelle, Cambridge, MA .....	05/06/97		
Lee, Kyong Mu, La Palma, CA .....	04/23/97		
Lim, Jhang Hyung, Fresno, CA .....	05/06/97		
Loughead, Thomas R, Pittsburgh, PA .....	04/30/97		
Mark, Jeffrey, Berkeley, CA .....	05/06/97		
Matalon, Ofer I, Santa Rosa, CA .....	05/06/97		
McDonough, Lawrence P, Rumson, NJ .....	05/04/97		
McGregor, Floyd A, Huntington Park, CA .....	04/23/97		
McLeod, Herbert W, Lawrenceville, GA .....	05/05/97		
McWhinnie, Clarence E Jr, Los Angeles, CA .....	05/06/97		
Miller, Bradley G, Los Angeles, CA .....	04/23/97		
Millns, Mark C, Toledo, OH .....	04/28/97		
Monk, Melcher F, Bronx, NY .....	05/04/97		

Dated: April 9, 1997.

**William M. Libercci,**

Director, Health Care Administrative Sanctions, Office of Enforcement and Compliance.

[FR Doc. 97-12763 Filed 5-14-97; 8:45 am]

BILLING CODE 4150-04-P

**DEPARTMENT OF HEALTH AND HUMAN SERVICES****National Institutes of Health****Submission for OMB Review; Comment Request**

**SUMMARY:** Under the provisions of Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995, the National Cancer Institute (NCI), the National Institutes of Health (NIH) has submitted to the Office of Management and Budget

(OMB) a request to review and approve the information collection listed below. This proposed information collection was previously published in the **Federal Register** on December 16, 1996, page 66053 and allowed 60 days for public comment. No public comments were received. The purpose of this notice is to allow an additional 30 days for the public comment. The National Institutes of Health may not conduct or sponsor, and the respondent is not required to respond to, an information collection that has been extended, revised, or implemented on or after October 1, 1995, unless it displays a currently valid OMB control number.

**PROPOSED COLLECTION:** Title: NCI Cancer Information Service Demographic/ Customer Service Data Collection. *Type of Information Collection Requested:* Reinstatement with change of a currently approved collection. *Form Number:* 0937-0201. *Need and Use of Information Collection:* The CIS provides the general public, cancer patients, families, health professionals, and others with the latest information on cancer. Essential to providing the best customer service is the need to collect data about callers and how they found out about the service. This effort involves asking seven questions to five categories of callers for an annual total of approximately 378,165 callers. *Frequency of Response:* Single time. *Affected Public:* Individuals or households. *Type of Respondents:* Patients, relatives, friends, and general public. The annual reporting burden is as follows: *Estimated Number of Respondents:* 378,165; *Estimated Number of Responses per Respondent:* 1; *Average Burden Hours Per Response:* 0162; and *Estimated Total Annual Burden Hours Requested:* 6,126. The annualized cost to respondents is estimated at: \$76,693. There are no Capital Costs to report. There are no Operating or Maintenance Costs to report.

Type of respondents	Estimated number of respondents	Estimated number of responses per respondent	Average burden hours per response	Estimated total annual burden hours requested
Individuals or households .....	378,165	1	.0162	6,126
Total .....				6,126

**Request for Comments**

Written comments and/or suggestions from the public and affected agencies are invited on one or more of the following points: (1) Whether the proposed collection of information is

necessary for the proper performance of the function of the agency, including whether the information will have practical utility; (2) The accuracy of the agency's estimate of the burden of the proposed collection of information, including the validity of the

methodology and assumptions used; (3) Ways to enhance the quality, utility, and clarity of the information to be collected; and (4) Ways to minimize the burden of the collection of information on those who are to respond, including the use of appropriate automated,

electronic, mechanical, or other technological collection techniques or other forms of information technology.

#### Direct Comments to OMB

Written comments and/or suggestions regarding the item(s) contained in this notice, especially regarding the estimated public burden and associated response time, should be directed to the: Office of Management and Budget, Office of Regulatory Affairs, New Executive Office Building, Room 10235, Washington, DC 20503, Attention: Desk Officer for NIH. To request more information on the proposed project or to obtain a copy of the data collection plans and instruments, contact: Chris Thomsen, Chief, Cancer Information Service Branch, OCC, OD, NCI, Building 31, Room 10A16, 9000 Rockville Pike, Bethesda, MD 20892, or call non-toll-free number (301) 496-5583 ext. 239 or E-mail your request, including your address to: thomsenc@occ.nci.nih.gov

#### Comments Due Date

Comments regarding this information collection are best assured of having their full effect if received on or before June 16, 1997.

Dated: May 6, 1997.

Nancie L. Bliss,

OMB Project Clearance Liaison.

[FR Doc. 97-12782 Filed 5-14-97; 8:45 am]

BILLING CODE 4140-01-M

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Government-Owned Inventions; Availability for Licensing

**AGENCY:** National Institutes of Health, HHS.

**ACTION:** Notice.

The inventions listed below are owned by agencies of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for U.S. companies and may also be available for licensing.

**ADDRESSES:** Licensing information and copies of the U.S. patent applications listed below may be obtained by writing to the indicated licensing contact at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville,

Maryland 20852-3804 (telephone 301/496-7057; fax 301/402-0220). A signed Confidential Disclosure Agreement (CDA) will be required to receive copies of the patent applications.

#### Agents That Bind To and Inhibit Human Cytochrome P450 2D6

HV Gelboin, FJ Gonzalez, KW Krausz (NCI)  
OTT Ref. No. E-46-97/0 filed 22 Jan. 97  
Licensing Contact: Leopold J. Luberecki, Jr., 301/496-7735 ext 223

This invention concerns monoclonal antibodies (MAbs) and other binding agents specific for the 2D6 subgroup of cytochrome P450 enzymes. The cytochrome P450s are the metabolic interface between xenobiotics and their metabolism in human and other species as well as for the metabolism of endobiotics. A large array of drugs, mutagens, carcinogens, pesticides, environmental chemicals, fatty acids, bile acids, and steroids are metabolized by individual forms of cytochrome P450. The invention involves the construction, isolation, and production of MAbs that specifically bind to human cytochrome P450 and 2D6 and that specifically inhibit the enzyme activity of human cytochrome P450 and lack specific binding to other human cytochrome P450s. These MAbs can be used to assess adverse reactions in patients to compounds and to identify populations that would exhibit different sensitivities to the therapeutic or toxic effects of compounds. Cytochrome P450 2D6, also known as debrisoquine hydroxylase, is the best characterized polymorphic P450 in the human population. Genetic differences in cytochrome P450 2D6 may be associated with increased risk of developing environmental and occupational based diseases. In addition, several drugs for treating cardiovascular and psychiatric disorders are known substrates of cytochrome P450 2D6, and these compounds could be more readily prescribed to normal metabolizers as assessed using the MAbs described in the invention. The list of compounds includes  $\beta$ -blockers and antiarrhythmics, psychoactive drugs including tricyclic antidepressants, and a variety of other commonly used drugs including codeine and dextromethorphan. A provisional patent application for this invention has been filed with the U.S. Patent and Trademark Office (PTO).

An adjunct technology to this invention that is available for licensing involves two inhibitory monoclonal antibodies to human P450 3A4 and human P450 2E1 that have been developed and filed as a separate patent

application (U.S. Serial No. 08/599,808) with the PTO. The P450 3A4 has likely the largest number of known drug substrates than any other P450. The P450 2E1 also metabolizes some drugs and has high activity towards smaller molecules which are found in the environment and which may be toxic. (portfolios: Internal Medicine—Research Materials; Cancer—Research Materials, MAb based; Internal Medicine—Diagnostics; Cancer—Diagnostics, in vitro, MAb based)

#### Vanilloid Agonists for Desensitization of C-Fiber Sensory Afferent Neurons

PM Blumberg, T Biro, P Acs, G Acs (NCI)

Serial No. 60/030,999 filed 15 Nov 96  
Licensing Contact: Leopold J. Luberecki, Jr., 301/496-7735 ext 223

Capsaicin has been proven to have therapeutic utility in the treatment of arthritis, pruritis, bladder hyperreflexia, allergic responses including rhinitis, and pain, including pain associated with cancer, peripheral neuropathies, and postherpetic neuralgia. For a number of these indications, applications have been found in veterinary as well as human medicine. Recent advances have identified capsaicin analogs with ultrapotency and with a more favorable spectrum of action, as well as subclasses of capsaicin receptors with different effects on desensitization. This invention describes a method of administering to a capsaicin-sensitive animal a therapeutically effective combination of capsaicin agonists and capsaicin-like antagonists which are more effective than the agonist alone at desensitizing a vanilloid responsive cell, and thereby improve the therapeutic index of the capsaicin agonist and overall treatment. Also described are pharmaceutical compounds which are effective in this method. (portfolios: Central Nervous System—Therapeutics, neurological, narcotics and analgesics; Internal Medicine—Therapeutics, other)

#### Sustained-Release Derivatives of Hydroxylated Analogs of Substituted 1-[2[bis(aryl)methoxy]-ethyl]-Piperazines and Homopiperazines and Their Use As Noncompetitive Antagonists of Dopamine Reuptake Inhibitors

RB Rothman (NIDA), KC Rice (NIDDK), DB Lewis (NIDDK), D Matecka (NIDDK), JR Glowa (NIDDK)

Serial No. 60/030,248 filed 31 Oct 96  
Licensing Contact: Leopold J. Luberecki, Jr., 301/496-7735 ext 223

Cocaine abuse and addiction is a major public health problem in the United States and several other